Sign up to access historical data
Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$520,000 |
 |
Gilead SciencesGILD |
-$2.35B |
 |
Anavex Life SciencesAVXL |
-$6.3M |
 |
AmgenAMGN |
-$169M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| O'Neill Gilmore Neil | Mar 3, 2026 | Sell | 5,394 | $2.0197 | $11,000 |
| Parison Amy | Mar 3, 2026 | Sell | 474 | $2.02 | $960 |
| Burkly Linda | Mar 3, 2026 | Sell | 749 | $2.0196 | $1,500 |
| O'Neill Gilmore Neil | Dec 3, 2025 | Sell | 5,603 | $2.1531 | $12,000 |
| Burkly Linda | Dec 3, 2025 | Sell | 713 | $2.1531 | $1,500 |
| Parison Amy | Dec 3, 2025 | Sell | 461 | $2.1531 | $990 |
| O'Neill Gilmore Neil | Sep 3, 2025 | Sell | 5,592 | $2.5961 | $15,000 |
| Burkly Linda | Sep 3, 2025 | Sell | 710 | $2.5961 | $1,800 |
| Parison Amy | Sep 3, 2025 | Sell | 458 | $2.5961 | $1,200 |
| Parison Amy | Aug 7, 2025 | Sell | 679 | $2.58 | $1,800 |
| Burkly Linda | Jul 31, 2025 | Sell | 5,121 | $2.4911 | $13,000 |
| O'Neill Gilmore Neil | Jun 3, 2025 | Sell | 15,192 | $1.7243 | $26,000 |
| Parison Amy | Jun 3, 2025 | Sell | 446 | $1.724 | $770 |
| Burkly Linda | Jun 3, 2025 | Sell | 726 | $1.7243 | $1,300 |
| O'Neill Gilmore Neil | Mar 4, 2025 | Sell | 16,632 | $1.7107 | $28,000 |
| Lucera Erick | Mar 4, 2025 | Sell | 4,109 | $1.7108 | $7,000 |
| Burkly Linda | Mar 4, 2025 | Sell | 2,891 | $1.7107 | $4,900 |
| O'Neill Gilmore Neil | Dec 3, 2024 | Sell | 1,618 | $2.0774 | $3,400 |
| Mei Baisong | Dec 3, 2024 | Sell | 541 | $2.0772 | $1,100 |
| O'Neill Gilmore Neil | Sep 4, 2024 | Sell | 1,555 | $3.4247 | $5,300 |
| Mei Baisong | Sep 4, 2024 | Sell | 518 | $3.4247 | $1,800 |
| Burkly Linda | Jul 25, 2024 | Sell | 11,886 | $5.4156 | $64,000 |
| Mei Baisong | Jul 19, 2024 | Sell | 6,619 | $5.2056 | $34,000 |
| O'Neill Gilmore Neil | Jun 4, 2024 | Sell | 12,191 | $5.4956 | $67,000 |
| Mei Baisong | Jun 4, 2024 | Sell | 511 | $5.4956 | $2,800 |
| Lucera Erick | May 20, 2024 | Sell | 22,337 | $5.6142 | $130,000 |
| Hopfield Jessica | May 13, 2024 | Buy | 45,000 | $5.6415 | $250,000 |
FAQ - Insider Transactions
The most recent insider transaction for Editas Medicine was conducted by O'Neill Gilmore Neil, who sold 5,394 shares on March 3, 2026 at a price of $2.02 per share.
Hopfield Jessica has bought the most EDIT stock in the last 2 years, with a total value of $250,000.
O'Neill Gilmore Neil has sold the most EDIT stock in the last 2 years, with a total value of $170,000.
The total value of insider transactions for Editas Medicine in the last 2 years is negative, amounting to -$180,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Editas Medicine have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
